This results in extramedullary hematopoiesis in other parts of the body, most notably the spleen, which is often enlarged. There are a number of therapeutic options to treat splenomegaly in ...

(Nasdaq: FBLG) , a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts ...

Splenomegaly, or an enlarged spleen, often occurs in connection with immune-related conditions and is seen in a variety of diseases, including autoimmune disorders and chronic infections.

There is a simple discount patient access scheme for fedratinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

FibroBiologics (FBLG) announced the filing of a patent application covering methods for treatment of splenomegaly using a cell-based ...

A decade after the discovery of CALR, the results are the first for a possible therapy for CALR-mutated MPNs to reach the ...

FBLG READ THE FULL FBLG RESEARCH REPORT Business Update On Track to Initiate Phase 1/2 Trial in Diabetic Foot Ulcers FibroBiologics, Inc. (NASDAQ:FBLG) is on track to initiate a Phase 1/2 trial of ...

A thrombopoietin agonist raises platelet counts in HCV-positive patients who are undergoing antiviral therapy. Cirrhotic patients who are infected with hepatitis C virus (HCV) often experience ...